High Versus Low LMWH Dosages in Hospitalized Patients With Severe COVID-19 Pneumonia and Coagulopathy
Status:
Not yet recruiting
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
Randomized, controlled study conducted in hospitalized patients with severe COViD-19
pneumonia and coagulopathy not requiring invasive mechanical ventilation.
Aim of this study is to assess whether high doses of Low Molecular Weight Heparin (LMWH) (ie.
Enoxaparin 70 IU/kg twice daily) compared to standard prophylactic dose (ie, Enoxaparin 4000
IU once day) are:
1. More effective to prevent clinical worsening, defined as the occurrence of at least one
of the following events, whichever comes first, during hospital stay:
1. Death
2. Acute Myocardial Infarction [AMI]
3. Objectively confirmed, symptomatic arterial or venous thromboembolism [TE]
4. Need for either non-invasive - Continuous Positive Airway Pressure (Cpap) or
Non-Invasive Ventilation (NIV) - or invasive mechanical ventilation for patients
who are in standard oxygen therapy by delivery interfaces at randomisation
5. Need for invasive mechanical ventilation for patients who are in non-invasive
mechanical ventilation at randomisation
2. Similar in terms of major bleeding risk during hospital stay